Skip to content
OpenCapital
Get started

Larimar Therapeutics LRMR Q1 2026 earnings

Reported May 14, 2026 · Before market open

Diluted EPS-$0.31Beat by $0.22
EPS estimate-$0.53

Next report

Aug 13, 2026 (in a month)
EPS estimate-$0.39

Versus estimates

Revenue

Q4 2024$241.0K

Diluted EPS

Q1 2026-$0.31Beat by $0.22
Q4 2025-$0.73Miss by $0.29Q3 2025-$0.61Miss by $0.22Q2 2025-$0.41Beat by $0.06Q1 2025-$0.46Miss by $0.04Q4 2024-$0.45Miss by $0.16

Ask the moment Larimar Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Larimar Therapeutics report Q1 2026 earnings?
Larimar Therapeutics (LRMR) reported Q1 2026 earnings on May 14, 2026 before market open.
What were Larimar Therapeutics's Q1 2026 revenue and EPS?
Larimar Therapeutics reported diluted EPS of $-0.31 for Q1 2026.
Did Larimar Therapeutics beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.53 by $0.22.
How did Larimar Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 32.6% from $-0.46.
Where can I find Larimar Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-222746) and the 10-Q periodic report (0001193125-26-224087) directly on SEC EDGAR. The filing index links above go to sec.gov.